Arrowhead Pharmaceuticals Inc. (ARWR) concluded trading on Wednesday at a closing price of $34.00, with 5.05 million shares of worth about $171.72 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.92% during that period and on on Wednesday the price saw a gain of about 9.10%. Currently the company’s common shares owned by public are about 123.90M shares, out of which, 116.58M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 15 times over the past 12 months. They bought 162,683 shares in 3 of the transactions. In 12 selling transactions, insiders dumped 233,346 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of 16.52% in past 5 days and over the past one month there was a price change of -1.16%. Year-to-date (YTD), ARWR shares are showing a performance of 11.11% which increased to 4.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $20.67 but also hit the highest price of $42.48 during that period. The average intraday trading volume for Arrowhead Pharmaceuticals Inc. shares is 1.67 million. The stock is currently trading 9.28% above its 20-day simple moving average (SMA20), while that difference is up 5.67% for SMA50 and it goes to 10.68% higher than SMA200.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) currently have 123.90M outstanding shares and institutions hold larger chunk of about 62.56% of that.
The stock has a current market capitalization of $4.21B and its 3Y-monthly beta is at 0.72. It has posted earnings per share of -$2.77 in the same period. It has Quick Ratio of 3.73 while making debt-to-equity ratio of 2.45. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARWR, volatility over the week remained 8.06% while standing at 5.73% over the month.
Analysts are in expectations that Arrowhead Pharmaceuticals Inc. (ARWR) stock would likely to be making an EPS of -$0.16 in the current quarter, while forecast for next quarter EPS is -$0.63 and it is -$2.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.95 which is $3.27 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.45 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -40.09% while it is estimated to increase by 8.01% in next year. EPS is likely to grow at an annualized rate of 7.33% for next 5-years, compared to annual growth of -24.19% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on December 04, 2023 offering a Buy rating for the stock and assigned a target price of $29 to it. Coverage by Citigroup stated Arrowhead Pharmaceuticals Inc. (ARWR) stock as a Neutral in their note to investors on September 19, 2023, suggesting a price target of $33 for the stock. On July 21, 2023, TD Cowen Initiated their recommendations, while on May 12, 2023, SVB Securities Downgrade their ratings for the stock with a price target of $40. Stock get an Outperform rating from SMBC Nikko on April 26, 2023.
